Marketing and Licensing Agreements
Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
Published in Cardiovascular Device Liability Week, February 3rd, 2008
Vytorin is the combination of Zetia and Zocor, a statin now available as a generic drug for about one-third of the cost.
The investigation centers around charges that the companies have known since 2006 that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Cardiology
Research on cardiology discussed by scientists at University of York, Department of Health Sciences - Cardiovascular Disease
Findings in cardiovascular disease reported from D.W. Glover and co-researchers - Heart Attack Therapy
New heart attack therapy research reported from Tufts University, Institute for Clinical Research and Health Policy Studies - Heart Disease
Patient Advocacy Leaders and Health Policy Professionals Join Forces to Change the Paradigm for Care - Marketing and Licensing Agreements
Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough - Research and Markets Ltd.
Patients Become Plaintiffs Will Provide Readers with All They Need to Know about Product Liability Regulation to Protect Their Business - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
